一分钟看懂
这是一项关于晚期实体瘤的II 期研究，登记的药物或干预包括HER3-DXd，当前状态为招募中。登记地点显示中国成都、广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HER3-DXd · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West China Hospital, Sichuan University · 成都
- Sun Yat-sen University Cancer Center · 广州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Participants must meet all of the following criteria to be eligible for enrollment into the study:
- 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.
- 2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
- 3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:
- Cutaneous (acral and non-acral) melanoma
- 1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma
- 2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \[ICIs\] \[ie, anti-CTLA4, anti- LAG-3\] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF/MEK inhibitor therapy as well.
- Squamous cell carcinomas of the head and neck
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06172478；登记信息更新于 2026-10-01；本站同步于 2026-10-08。